Interview: Antonino Reale – CEO, Daiichi Sankyo Italy
Antonino Reale, who has managed Daiichi-Sankyo Italy for the last 12 years, explains the reasoning and strategy…
Daiichi Sankyo Italy
Last updated: 11.12.2015
Daiichi Sankyo, founded in 2006 by the merger of Japanese companies Daiichi and Sankyo in Europe, is a global pharmaceutical group with over 100 years of scientific research behind it and a presence in over 20 countries worldwide. In Italy the company has extensive commercial and research operations, with a turnover of 67 million euros in 2015. The country is seen as a growth driver for the group in Europe.
Contact
Address: Via Paolo di Dono, 73, 00144 Roma,Italy
Tel: -6852512
Web: http://www.daiichi-sankyo.it/
Interviews
Interview with Antonino Reale, President, Daiichi Sankyo Italy
When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the…
Related
Italy / Market Access Reform: A Watershed Moment?
In recent months, a profound transformation has been occurring right at the core of the Italian pharmaceutical…
Italy / Mandatory COVID-19 Vaccines for Healthcare Workers; Chiesi & Angelini’s AI Investments; Sputnik V Manufacturing
The latest Italy Pharma News, including the government’s decision to make COVID-19 vaccines mandatory for all…
Italy / Stevanato’s $5 bn valuation; Zolgensma Approval; Sputnik V Manufacturing
The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine…
Italy / Menarini CEO on Averting Future Health Crises; Alfasigma Hackathon; January COVID Vaccines
A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with…
Pricing / Italy Takes Global Transparency Lead by Forcing Pharma to Disclose Public R&D Funding
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding…
News Roundup / Italy Pharma July 2020
Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline…
M&A / Menarini Makes Big US Oncology Move with Stemline Acquisition
Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US…
Internationalization / Chiesi Moves into Rare Diseases & the US Market
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based…
Interview: Luca G. Guidotti – Deputy Scientific Director, San Raffaele…
Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community,…
Interview: Gianvito Martino – Scientific Director & Director of the…
The division of neuroscience at the San Raffaele Scientific Institute is one of the best worldwide performers in…
Interview: Angelo Corti – Director, Division of Experimental Oncology, San…
Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to…
Interview: Paola Pozzi – Head, Office of Biotechnology Transfer, San…
Dr. Paola Pozzi, the head of the Office of Biotechnology Transfer at the San Raffaele Scientific Institute,…
